Description |
1 online resource |
Series |
RSC drug discovery ; 45 |
|
RSC drug discovery series ; 45.
|
Contents |
880-01 Cover; Contents; Introduction; Chapter 1 The Relevance of Biomarkers, Risk Factors and Gene-Environment Interactions in Disease: Scientific Developments and Therapeutic Approaches; 1.1 Introduction; 1.2 Biomarkers of Disease; 1.3 Risk Factors of Disease; 1.4 Gene-Environment Interactions in Disease; 1.5 Drug Development and Targeted Therapies; 1.6 Conclusion; References; Part 1 Obesity; Chapter 2 Molecular Links between Obesity, Hypertension and Metabolic Dysfunction; 2.1 Introduction; 2.2 Consequences of Obesity on Cardiovascular and Metabolic Disease |
|
880-01/(S 3.3 Adiposity and Adipose Tissue3.3.1 White, Brown and Beige Adipose Tissue; 3.3.2 Abdominal Body Fat Distribution Patterns; 3.3.3 Subcutaneous versus Visceral Adipose Tissue; 3.3.4 White Adipose Tissue Function and Adipocyte Size; 3.4 Adipokines; 3.4.1 Leptin; 3.4.2 Adiponectin; 3.5 Inflammation; 3.5.1 TNF-α ; 3.5.2 IL-6; 3.5.3 CRP; 3.6 Omics/Novel Biomarkers of Obesity and Risk of Further Metabolic Disease; 3.7 Conclusions; References; Chapter 4 Risk Factors for Obesity; 4.1 Introduction; 4.2 Obesity Can be Caused by Genetic and Other Diseases; 4.3 Obesity Can be Caused by Drugs |
|
2.3 Role of the SNS in Obesity-related Hypertension2.4 Contribution of Leptin and Insulin to Obesity-related Hypertension; 2.5 Role of Pro-opiomelanocortin Neurons; 2.6 Contribution of Neuropeptide Y; 2.7 Contribution of Ghrelin; 2.8 Effects of Obesity Across Generations; 2.9 The Influence of Aversive Stress on Obesity-related Hypertension; 2.10 Conclusions; References; Chapter 3 Discovery of Biomarkers of Obesity; 3.1 Introduction; 3.2 Identifying and Classifying Obese Individuals; 3.2.1 Classifying Obesity in Adults; 3.2.2 Classifying Obesity in Infants and Children |
|
4.4 The High Fat Food Problem4.5 Why is Dietary Fat a Problem?; 4.6 Alcohol is the Worst Obesogen; 4.7 Fad Foods and Obesity; 4.8 Toxic Fats; 4.9 Bad Carbohydrates, Empty Calories and High Glycemic Index; 4.10 Childhood Obesity; 4.11 Sedentary Lifestyles; 4.12 Why is Exercise so Important?; 4.13 Present Lessons for the Future; References; Chapter 5 Gene-Environment Interactions in Obesity; 5.1 Introduction; 5.2 Definition and Methods Used in the Assessment of Obesity; 5.3 Genetics and Obesity; 5.4 Animal Models and the Genetics of Obesity; 5.4.1 Spontaneous Animal Models of Obesity |
|
5.4.2 Genetically Engineered Animal Models of Obesity5.5 Genetic Approaches to Studying Human Obesity; 5.6 Epigenetics and Obesity; 5.7 Environmental Genetic Interactions in Obesity; 5.8 Summary; References; Chapter 6 New Drug Design and Therapeutic Development for Weight Reduction: Preclinical Studies and Clinical Trials; 6.1 Obesity and its Metabolic Consequences; 6.1.1 The Strategic and Commercial Landscape of Drug Intervention; 6.2 Preclinical Studies; 6.2.1 CNS Approaches; 6.2.2 Peripheral Approaches; 6.3 Clinical Studies; 6.3.1 Lorcaserin; 6.3.2 Phentermine |
Summary |
Cardiovascular and metabolic diseases remain the number one cause of death in developed countries and their prevalence is increasing rapidly in developing nations. This book brings together the recent information on these disorders and the links that exist between them in order to provide a complete picture of drug discovery for these conditions. The main three sections comprehensively discuss obesity, hypertension and cardiovascular disease, and diabetes in turn, following an introduction to the molecular links between them. The final chapter provides perspectives on future directions of the field. Chapters are contributed by leaders in the field from academia and industry and cover biomarkers, risk factors, gene-environment interactions, therapies and the various types of animal models that have been used to study each disease. Case studies describing the implementation of animal models in drug development further enhance the book's usefulness as a comprehensive guide to this important therapeutic area. Providing a full picture of the various types of animal models that have been used to study obesity, hypertension, and insulin resistance with recent case studies, this book provides a valuable resource for medicinal chemists and clinicians working in these disease areas |
Notes |
Includes index |
|
English |
|
Online resource; title from PDF title page (Royal Society of Chemistry, viewed August 17, 2015) |
Subject |
Cardiovascular system -- Diseases.
|
|
Metabolism -- Disorders.
|
|
Cardiovascular system -- Diseases -- Treatment.
|
|
Metabolism -- Disorders -- Treatment
|
|
Diseases.
|
|
Causation.
|
|
Insulin resistance.
|
|
Risk.
|
|
Probabilities.
|
|
Pharmaceutical chemistry.
|
|
Insulin shock.
|
|
Statistics.
|
|
Chemistry.
|
|
Pharmacology.
|
|
Public health.
|
|
Life sciences.
|
|
Physical sciences.
|
|
Medical care.
|
|
Drugs -- Design.
|
|
Metabolic syndrome.
|
|
Disease
|
|
Metabolic Diseases
|
|
Causality
|
|
Drug Discovery
|
|
Insulin Resistance
|
|
Risk
|
|
Epidemiologic Factors
|
|
Probability
|
|
Investigative Techniques
|
|
Chemistry, Pharmaceutical
|
|
Nutritional and Metabolic Diseases
|
|
Hyperinsulinism
|
|
Statistics as Topic
|
|
Chemistry
|
|
Pharmacology
|
|
Analytical, Diagnostic and Therapeutic Techniques and Equipment
|
|
Quality of Health Care
|
|
Public Health
|
|
Glucose Metabolism Disorders
|
|
Biological Science Disciplines
|
|
Health Care Evaluation Mechanisms
|
|
Health Care Quality, Access, and Evaluation
|
|
Epidemiologic Methods
|
|
Natural Science Disciplines
|
|
Environment and Public Health
|
|
Delivery of Health Care
|
|
Disciplines and Occupations
|
|
Drug Design
|
|
Risk Factors
|
|
Metabolic Syndrome
|
|
Cardiovascular Diseases
|
|
Patient Care
|
|
probability.
|
|
chemistry.
|
|
pharmacology.
|
|
public health.
|
|
biological sciences.
|
|
physical sciences.
|
|
statistics.
|
|
Diseases & disorders.
|
|
Pharmacology.
|
|
MEDICAL -- Pharmacology.
|
|
SCIENCE -- Life Sciences -- Biochemistry.
|
|
Statistics
|
|
Risk
|
|
Public health
|
|
Probabilities
|
|
Physical sciences
|
|
Pharmacology
|
|
Pharmaceutical chemistry
|
|
Metabolic syndrome
|
|
Medical care
|
|
Life sciences
|
|
Insulin shock
|
|
Insulin resistance
|
|
Drugs -- Design
|
|
Diseases
|
|
Chemistry
|
|
Causation
|
|
Cardiovascular system -- Diseases
|
|
Cardiovascular system -- Diseases -- Treatment
|
|
Metabolism -- Disorders
|
|
Metabolism -- Disorders -- Treatment
|
Form |
Electronic book
|
Author |
Peplow, Philip, editor
|
|
Adams, James, editor
|
|
Young, Tim, editor
|
|
Royal Society of Chemistry (Great Britain)
|
ISBN |
9781782622390 |
|
178262239X |
|
9781782625247 |
|
1782625240 |
|
178262046X |
|
9781782620464 |
|